Error-free repair of DNA double-strand breaks (DSBs) is achieved by homologous recombination (HR), and BRCA1 is an important factor for this repair pathway 1 . In the absence of BRCA1-mediated HR, the administration of PARP inhibitors induces synthetic lethality of tumour cells of patients with breast or ovarian cancers 2, 3 . Despite the benefit of this tailored therapy, drug resistance can occur by HR restoration 4 . Genetic reversion of BRCA1-inactivating mutations can be the underlying mechanism of drug resistance, but this does not explain resistance in all cases 5 . In particular, little is known about BRCA1-independent restoration of HR. Here we show that loss of REV7 (also known as MAD2L2) in mouse and human cell lines re-establishes CTIP-dependent end resection of DSBs in BRCA1-deficient cells, leading to HR restoration and PARP inhibitor resistance, which is reversed by ATM kinase inhibition. REV7 is recruited to DSBs in a manner dependent on the H2AX-MDC1-RNF8-RNF168-53BP1 chromatin pathway, and seems to block HR and promote end joining in addition to its regulatory role in DNA damage tolerance 6 . Finally, we establish that REV7 blocks DSB resection to promote non-homologous end-joining during immunoglobulin class switch recombination. Our results reveal an unexpected crucial function of REV7 downstream of 53BP1 in coordinating pathological DSB repair pathway choices in BRCA1-deficient cells.
To identify mechanisms of BRCA1-independent restoration of the HR pathway, we carried out a loss-of-function short hairpin RNA (shRNA) screen using the KB1P-B11 and KB1P-G3 cell lines that we previously derived from Brca1 2/2 p53 2/2 (p53 is also known as Trp53) mouse mammary tumours 7 ( Fig. 1a and Supplementary Table 1) . Resistant cells were selected with a high concentration of olaparib (500 nM, about 100-fold the half-maximal inhibitory concentration (IC 50 )), which killed cells of the empty vector control. Sequencing of the olaparib-surviving colonies revealed a reproducible enrichment of various individual hairpins targeting Rev7 or 53bp1 (also known as Trp53bp1). To validate the Rev7 hit, we introduced two different hairpins into the KB1P-B11 and KB1P-G3 cell lines; these substantially inhibited Rev7 expression (Fig. 1b, c and Extended Data Fig. 1a ). Despite the role of REV7 in metaphase-to-anaphase transition 8 , the level of Rev7 inhibition in these cells did not affect proliferation (Extended Data Fig. 1b, c) , allowing long-term clonogenic survival assays. We confirmed that loss of Rev7 resulted in increased resistance to the PARP inhibitors (PARPi) olaparib and AZD2461 (ref. 7) in both cell lines ( Fig. 1d and Extended Data Fig. 1d-g ). Resistant cells that survived olaparib treatment (Rev7 sh1/ 2-ola) yielded even lower REV7 expression levels and increased numbers of colonies after PARPi treatment (Fig. 1b-d and Extended Data Fig. 1h ). When we reconstituted the Rev7-depleted cells with shRNA-resistant Rev7 complementary DNA resulting in similar REV7 protein levels (Extended Data Fig. 1i ), we successfully re-sensitized the tumour cells to PARPi (Fig. 1e, f) .
Tumours derived from the Brca1 2/2 p53 2/2 cells with stable Rev7 inhibition also showed olaparib resistance in vivo, in contrast to the empty vector controls ( Fig. 1g and Extended Data Fig. 1j-l) . In addition, we found that Rev7 loss explains some cases of in vivo acquired PARPi resistance in BRCA1-deficient mouse mammary tumours (data not shown). REV7 depletion also resulted in PARPi resistance of the human BRCA1-deficient cell line SUM149PT (Extended Data Fig. 2 ). Together, these data strongly indicate that inhibition of Rev7 confers PARPi resistance in BRCA1-deficient tumour cells.
Together with the catalytic subunit REV3, REV7 forms the translesion synthesis polymerase f (Polf), and it interacts with REV1 (ref. 9 ). We therefore investigated whether loss of REV1 or REV3 also confers PARPi resistance in Brca1 2/2 p53 2/2 cells. A 60% inhibition of Rev1 or Rev3 transcripts did not cause olaparib resistance (Extended Data Fig. 3a-d) . Moreover, we studied various shRNA-resistant REV7 mutants that lack REV1 (Leu186Ala/Gln200Ala/Tyr202Ala and a 1-183-amino-acids truncated protein) or REV3 (Cys70Arg) binding sites 10, 11 . In contrast to the truncated 1-140-amino-acid REV7 protein, these mutants are recruited to DNA damage sites (Extended Data Fig. 3e-g ), and their expression in Rev7 shRNA KB1P-B11 and KB1P-G3 cells significantly restored the sensitivity to PARPi to a degree approaching that of wild-type REV7 ( Fig. 2a, b ; P , 0.001, t-test). The remaining differences of the Leu186Ala/Gln200Ala/Tyr202Ala or Cys70Arg mutants with wild-type REV7 may be explained by unequal expression levels (Extended Data Fig. 3f ). These data suggest that the REV1 or REV3 interaction is not absolutely required for the REV7-mediated function in this context.
We observed that green fluorescent protein (GFP)-tagged REV7 colocalizes with 53BP1 shortly after DNA damage induction, suggesting that REV7 acts directly at the site of DNA damage (Fig. 2c) . REV7 recruitment depends on H2AX, MDC1, RNF8, RNF168 and partly ATM, in both mouse and human cells ( tumour cells is due to HR restoration, we investigated RAD51 focus *These authors contributed equally to this work.
formation after 10 Gy ionizing radiation. As shown in Fig. 3a , b and Extended Data Fig. 4e , f, Rev7 loss resulted in the restoration of RAD51 foci formed after DNA damage. To exclude potential off-target effects of the hairpins, we reconstituted Rev7 shRNA1 and shRNA2 cells with shRNA-resistant mouse or human REV7-GFP fusion proteins (Extended Data Fig. 4g ). REV7 re-expression abolished RAD51 focus formation after DNA damage in GFP-positive cells (Fig. 3b) . We confirmed the re-appearance of RAD51 foci after tumour irradiation in vivo using computed tomography (CT)-guided high precision cone beam irradiation of animals carrying PARPi-resistant KB1P(M) tumours with low Rev7 gene expression (Fig. 3c) . We then tested whether the processing of broken DNA ends requires ATM in Rev7-depleted cells, and found that inhibition of ATM using KU55933 efficiently suppresses DNA-damage-induced RAD51 foci and increases olaparib sensitivity (Extended Data Fig. 4h, i) . Hence, the partial restoration of RAD51 focus formation in Brca1-deficient mammary tumour cells after DNA damage by inhibition of Rev7 is ATMdependent.
In contrast to the results with BRCA1-deficient cells, Rev7 depletion in BRCA2-deficient cells did not result in PARPi resistance (Extended Data Fig. 5a-f) . Furthermore, we did not observe increased PARPi resistance after Rev7 inhibition in the BRCA1/2-proficient p53 2/2 tumour cell line KP3.33 (Extended Data Fig. 5g-i ). This indicates that REV7 works upstream of BRCA2 and is antagonized by BRCA1. We therefore tested whether DNA end resection is altered in the absence of Rev7 in BRCA1-deficient cells. Accumulation of the single-strand binding protein, RPA, was used as a marker for the generation of singlestranded DNA (ssDNA). Cells were exposed to a particles 12 , and BRCA1 deficiency resulted in a marked decrease in RPA-positive a tracks compared to BRCA1-proficient cells (Fig. 3d, e) . REV7 depletion in the Brca1 2/2 p53 2/2 cells largely suppressed this defect in both KB1P-G3 and KB1P-B11 cells ( Fig. 3e and Extended Data Fig. 6a ). In addition to coating resected DNA ends, RPA also interacts with ssDNA gaps (for example, during replication) 13 . To exclude that the observed RPA accumulation reflected interaction with internal ssDNA gaps, we prevented DNA end resection (without influencing replication) by knocking down CTIP (ref. 14) . This eliminated the increase in RPA-positive tracks induced by Rev7 knockdown in Brca1 2/2 p53 2/2 cell lines ( Fig. 3f and Extended Data Fig. 6b ), without affecting cell cycle distribution (Extended Data Fig. 6c ). We therefore conclude that increased resection and not binding to ssDNA gaps is responsible for RPA accumulation. Hprt was used as a control for transcript expression, and b-tubulin was used as a control for protein expression. The data represent the mean 6 s.d. d, e, Long-term clonogenic assay using KB1P-G3 cells transduced with the indicated constructs (wt Rev7 stands for pLenti6-wt Rev7) and treatments. f, Quantification of the clonogenic assay in e by determining the absorbance of crystal violet at 590 nm. All the groups were normalized to the absorbance of the vector control. The data represent the mean 6 s.d. g, Overall survival of mice with KB1P-G3-derived Rev7-depleted or control tumours treated with one regimen of 50 mg olaparib per kilogram daily for 28 days or left untreated. The P value was calculated using the log-rank test. a, b, Long-term clonogenic assay (a) and quantification (b) using KB1P-G3 cells transduced with the indicated constructs (wt Rev7 stands for pMSCV-GFP-wt Rev7) and treatments. All groups were normalized to the absorbance of the shRev7-GFP control. The data represent the mean 6 s. 
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As Rev7 loss could restore end resection in BRCA1-deficient cells, we analysed whether its depletion could restore full HR proficiency in this context. Using mouse embryonic stem (mES) cells with a Brca1 selectable conditional knockout allele 15 , we observed that Rev7 loss indeed prevented cell death of mES cells after BRCA1 deletion, and restored RAD51 focus formation upon DNA damage (Extended Data Fig. 6d-h) . Moreover, we reproducibly observed a partial restoration of HR function in the DR-GFP reporter assay for homologous recombination 16 when Rev7 was depleted in BRCA1-deficient mES cells (Fig. 3g) .
Our data for REV7 are reminiscent of previous findings that 53BP1 loss occurs in subsets of human breast carcinomas 15 and can also restore HR to BRCA1-deficient cells 7, 15, 17 . As with 53BP1, we found a frequent aberrant reduction or loss of the REV7 protein in human triple-negative breast carcinomas (Extended Data Fig. 7 ). Addressing the relationship between REV7, 53BP1 and the 53BP1 non-homologous end-joining (NHEJ) effector protein, RIF1 (ref. 18) , we found that Rev7 deficiency did not compromise the formation of endogenous 53BP1 or RIF1 foci (Extended Data Fig. 8a-d) . By contrast, endogenous REV7 foci or laserinduced stripes were absent in 53BP1-depleted mouse and human cells ( Fig. 4a and Extended Data Fig. 4c, d ), strongly suggesting that REV7 acts downstream of 53BP1. This is also consistent with our results that PARPi resistance is not increased when both Rev7 and 53bp1 are depleted (data not shown). Despite such strong evidence for a cooperative role for REV7 and 53BP1, we did not detect REV7 in 53BP1 immunocomplexes isolated from untreated cell lysates, or ATM-phosphorylated 53BP1 immunocomplexes containing RIF1 that were induced by DNA damage 19 (Extended Data Fig. 8e and data not shown). Although the intricacies of the interactions remain to be determined, REV7 recruitment to DNA damage sites by 53BP1 may result from indirect interactions or an activity elicited by 53BP1 protein complexes in chromatin at DSB sites. 
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Rev7 sh2 To examine whether REV7, like 53BP1 (ref. 18) , also promotes NHEJ of DSBs during class switch recombination (CSR), we depleted Rev7 transcripts in the mouse CH12 B-cell line, which after stimulation undergoes CSR from IgM to IgA at a high rate 20 . Efficient Rev7 knockdown was achieved using several shRNAs, reducing CSR to levels comparable with 53BP1-depleted cells when compared to control-depleted cells ( Fig. 4b and Extended Data Fig. 9a, b) . Moreover, these defects were not accompanied by defects in cell proliferation, Aid (also known as Aicda), or germ-line transcript (mGLT/aGLT) expression (Extended Data Fig. 9c-e) . Conditional REV3-ablation has been reported to reduce CSR efficiency in B lymphocytes 21 , suggesting that distinct from 53BP1, REV7 might participate in CSR through Polf function. This considered, we reasoned that we might separate the function of REV7 from that of Polf during CSR, at the level of DSB resection inhibition. To this end, RPA enrichment was measured by chromatin immunoprecipitation (ChIP) at control and several IgH loci in control, 53BP1-, REV3-or REV7-depleted CH12 lines stimulated to undergo CSR. Consistent with the role of 53BP1 in resection inhibition, 53BP1-depletion was accompanied by a 3-5-fold enrichment of RPA ChIP signal specifically in donor (Sm) and acceptor (Sa) IgH switch (S) regions where DSBs occur during IgM to IgA CSR, but not at an IgH Sc1 locus or a control nonIgH Rpp30 locus (Fig. 4c) . Notably, these defects were closely mimicked after REV7 depletion, whereas shRNA-mediated REV3 depletion yielded no detectable increase in RPA IgH S-region enrichment, despite diminishing CSR efficiency (Extended Data Fig. 9f ) as expected 21 . Importantly, at each locus equivalent ChIP signals for total histone were obtained between cell lines. Thus, our data support a Polf-independent function of REV7 in inhibiting the nucleolytic processing of DSBs generated during CSR.
Our data uncover a crucial role for REV7 in regulating DSB repair. REV7 depletion restores homology-directed DNA repair of BRCA1-deficient cells resulting in PARPi resistance. We attribute this result to the inhibitory effect of REV7 on DNA end resection. Like 53BP1 together with RIF1 and PTIP (ref. 18 ), REV7 may function as a NHEJ factor that performs a regulatory role in DSB repair pathway choice. This provides new insight into the versatile functions of REV7 in addition to its role in translesion synthesis 9, 22 , and helps to explain how HR can be partially restored in the absence of BRCA1.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell culture and reagents. KB1P-B11 (B11) and KB1P-G3 (G3) cell lines were derived from a Brca1 2/2 p53 2/2 mouse mammary tumour as described 7 SCo/D ) 15 were cultured on gelatin-coated plates in 60% buffalo red liver cell-conditioned medium supplied with 10% FCS, 0.1 mM bmercaptoethanol (Merck) and 1 3 10 3 U ml 21 ESGRO LIF (Millipore) under normal oxygen conditions (21% O 2 , 5% CO 2 , 37 uC). CH12 cells (CH12F3-2) were cultured in RPMI-1640 medium (Sigma) supplemented with 10% FBS, 5% NCTC 109 medium (Sigma), 50 mM b-mercaptoethanol, 50 U ml 21 penicillin and 50 ng ml 21 streptomycin under normal oxygen conditions. Olaparib and AZD2461 were provided by AstraZeneca; KU-55933 (KuDOS) was bought from Selleckchem (S1092).
Lentivirus-based transduction of cells with shRNA. Glycerol stocks of shRNA hairpins were obtained from the Sigma Mission library (TRC 1.0) and isolation of plasmids was carried out with the high pure plasmid Mini Kit or Genopure maxi kit (Roche). 293T cells were seeded 16 h before transfection. For each 10-cm dish, 0.5 ml 23 HBS (8.18 g NaCl, 0.2 g Na 2 HPO 4 -7H 2 O, 5.95 g HEPES in 500 ml MilliQ water at pH 7.01) was added into a sterile falcon tube. In another sterile falcon tube, 6 mg plasmid DNA of interest, 2 mg pHCMV-G envelope vector (pMD.G), 2 mg pRSV-Rev, 2 mg packaging vector pMDLg/pRRE, 250 ml 0.5 M CaCl 2 and distilled water were added to bring up to 0.5 ml. The CaCl 2 /plasmid DNA mix was added to the 23 HBS and incubated for 20 min and then added to the cells. Medium was refreshed after 6 h and another 18 h, respectively. The supernatant of 293T cells containing lentivirus was collected after 24 h to infect cells with polybrene (6 mg ml
21
) for 12 h. The medium was refreshed after lentivirus infection and the cells were selected with puromycin. Individual shRNA vectors used were collected from the TRC library. Mouse Rev7: sh1: TRCN0000012844_CCAGTGGAGAAGTTTGTCTTT; sh2: TRCN 0000012846_CATCTTCCAGAAGCGCAAGAA; sh3: TRCN0000012847_GAT ACAGGTCATCAAGGACTT; human REV7: sh1: TRCN0000006569_CCCTGA TTCCAAGTGCTCTTA; sh2: TRCN0000006570_CCCGGAGCTGAATCAGTA TAT; sh3: TRCN0000006571_CCCAGTGGAGAAATTCGTCTT; sh4: TRCN00 00006573_CATCTTCCAGAAACGCAAGAA; mouse 53bp1: (puromycin) sh: TRCN0000081778_GCTATTGTGGAGATTGTGTTT; (neomycin) sh: same sequences as above; human 53BP1: sh1: TRCN0000018866_CCAGTGTGATTAGT ATTGATT; sh2: TRCN0000018865_GATACTTGGTCTTACTGGTTT; mouse p53: (neomycin) TRCN0000054551_AGAGTATTTCACCCTCAAGAT; mouse Rev1: sh1: TRCN0000120298_GCCGAGATCAACTATGGAATA; sh2: TRCN 0000120297_CAGCAGTGCTTGTGAGGTATT; mouse Rev3: sh1: TRCN0000 119969_CCGTCACATTAGTGAGACTAT; sh2: TRCN0000119970_GCCCAC ATACACTTTCTTCTT. Loss-of-function screen. In total, 1,976 lentiviral hairpins (pLKO.1) from the Sigma Mission library (TRC Mm 1.0) that target 391 mouse genes involved in the DNA damage response were selected (see Supplementary Table 1 ). This library was used to generate pools of lentiviral shRNA in 293T cells to infect target cells. After infection, the cells stably expressing integrated shRNA were selected with puromycin. Cells with HR restoration were selected with a high concentration of olaparib (500 nM, about 100-fold the IC 50 ), which killed cells of the empty vector group. Surviving cells were pooled and genomic DNA was extracted using the Gentra Puregene kit according to the manufacturer's protocol (Qiagen). shRNA inserts were retrieved from 50 ng genomic DNA by PCR amplification (PCR1 and PCR2) using the following conditions: (1) 95 uC, 5 min; (2) 95 uC, 30 s; (3) 60 uC, 30 s; (4) 72 uC, 1 min; (5) go to step (2), 20 cycles; (6) 72 uC, 5 min; (7) 4 uC. The PCR reaction system were as follows: 0.6 ml DMSO, 4.0 ml phusion HF buffer 53, 0.4 ml dNTPs, 1.0 ml primer f (10 mM), 1.0 ml primer r (10 mM), 11.8 ml mQ, 0.2 ml phusion,1.0 ml gDNA for PCR1 or 1 ml PCR1 products for PCR2. Adaptors and indexes for deep sequencing (Illumina HiSeq 2000) were incorporated into PCR primers as follows: PCR1 forward: PCR1_01_PLKO1_f_Integration determination_1, 59-AC ACTCTTTCCCTACACGACGCTCTTCCGATCTCGTGATCTTGTGGAAAG GACGAAACACCGG-39; PCR1_02_PLKO1_f_Integration determination_2, 59-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTAGCCCTTGTGGAAA GGACGAAACACCGG-39; PCR1_03_PLKO1_f_untreated_1, 59-ACACTCTT TCCCTACACGACGCTCTTCCGATCTCACTGTCTTGTGGAAAGGACGAA ACACCGG-39; PCR1_04_PLKO1_f_untreated_2, 59-ACACTCTTTCCCTAC ACGACGCTCTTCCGATCTATTGGCCTTGTGGAAAGGACGAAACACCGG -39; PCR1_05_PLKO1_f_olaparib_1, 59-ACACTCTTTCCCTACACGACGCTC TTCCGATCTGATCTGCTTGTGGAAAGGACGAAACACCGG-39; PCR1_06_ PLKO1_f_olaparib_2, 59-ACACTCTTTCCCTACACGACGCTCTTCCGATC TTCAAGTCTTGTGGAAAGGACGAAACACCGG-39; PCR1_07_PLKO1_f_ olaparib_3, 59-ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTGATC CTTGTGGAAAGGACGAAACACCGG-39; PCR1_08_PLKO1_f_olaparib_4, 59-ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGCTACTTGTGGAA AGGACGAAACACCGG-39; PCR1 reverse: P7_pLKO1_r, 59-CAAGCAGAAG ACGGCATACGAGATTTCTTTCCCCTGCACTGTACCC-39; PCR2 forward: P5_IlluSeq, 59-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTA CACGACGCTCTTCCGATCT-39; PCR2 reverse: P7, 59-CAAGCAGAAGACGG CATACGAGAT-39.
PCR2 products were purified using the PCR purification kit from Qiagen. The shRNA stem sequence was segregated and aligned to the TRC library. The reads of different hairpins were counted and the following criteria were used to select the top hits for further validation: (1) hairpins targeting the same gene in survival clones should have at least 1 3 10 4 reads (total ,6 3 10 6 reads); (2) at least two different hairpins targeting the same gene should be present; (3) hairpins in resistant clones should be highly enriched (.8-fold) in cells after olaparib selection; and (4) hairpins should be present in 4 out of 4 independent screens. PARPi treatment study. Long-term clonogenic assay: on day 0, 1.5 3 10 4 (B11) or 1 3 10 4 (G3, KB2P_1.21 or KB2P_3.4) or 6 3 10 3 (KP3.33) cells were seeded per well with PARPi (or untreated control) into six-well plates. The medium of the PARPi treatment groups was refreshed with PARPi every 4 days. On day 5, the untreated control group was stopped and the PARPi treatment groups were stopped after another 2-3 weeks and stained with 0.1% crystal violet. Using the SUM149PT cells, 4 3 10 4 cells were seeded per well with olaparib (or untreated control) into 12-well plates. The medium of the PARPi treatment groups was refreshed with olaparib every 4 days. On day 6, the untreated control group was stopped and the olaparib treatment groups were stopped on day 8 and stained with 0.1% crystal violet. Quantification of the clonogenic assay was done by determining the absorbance of crystal violet at 590 nm.
Short-term clonogenic assay: on day 0, 4 3 10 2 (G3) cells were seeded per well with olaparib (or untreated control) into 6-well plates. On day 4, the medium was refreshed with olaparib or untreated control. On day 8, all the groups were stained with Leishman dye and quantification was done by the relative colony numbers. ATM and PARP inhibitor combination study. On day 0, 1 3 10 4 (G3) cells were seeded per well into 6-well plates and then ATM inhibitor or olaparib or their combination was added. The medium was refreshed every 3 days with the different drugs. For the combination therapy groups, ATM inhibitor was applied for 6 days. On day 5, ATM inhibitor alone and untreated control groups were stopped and the other groups were stopped on day 12 and stained with 0.1% crystal violet. Constructs. Human REV7 was amplified by PCR using Platinum Taq polymerase (Invitrogen) from U2OS cDNA using the following primers 59-ATAGAATTC AATGACCACGCTCACACGACAAGAC -39 and 59-ATATGGTACCATCAGC TGCCTTTATGAGCGCGC-39. Mouse Rev7 was amplified from mouse lung cDNA in two parts to introduce silent mutations, making it resistant to Rev7 shRNA2 (mRev7R). The following primers were used for part A: The PCR product and pEGFP-C1 vector were digested using EcoRI and KpnI and ligated using the T4 DNA Ligase (Roche) to generate pEGFP-hREV7 and pEGFP-mREV7R.
Using pEGFP-mREV7R as a template, pEGFP-C1-based REV7 truncated constructs was amplified by PCR using the following primers: forward: 59-ATATGA ATTCGATGACCACCCTCACGCGC-39, reverse: mREV7R (1-55aa): 59-ATAT GGTACCGGACATCTGAACCGGCAC-39; mREV7R (1-81aa): 59-ATATGGT ACCCTCCACATCGTTCTTCTCCAGG-39; mREV7R (1-110aa): 59-ATATGG TACCGATGGACAGCAAGGGAGGC-39; mREV7R (1-140aa): 59-ATATGGT ACCGTTGTGATCCAGGACAGC-39; mREV7R (1-183aa): 59-ATATGGTACC GTCGTGCATGTGGACATCCTG-39. pEGFP-REV7 mutants (shRNA-resistant) were ordered as gBlocks (IDT) and cloned into the pEGFP-C1 vector using EcoRI and KpnI restriction enzymes and quick ligase (NEB). The DNA sequences that were ordered as gBlocks are: mREV7_shRNAresistant (mREV7R): CGCCGCG AATTCCGCCACCATGACCACCCTCACGCGCCAAGACCTCAACTTTGGC CAAGTGGTGGCTGACGTGCTCTCCGAGTTCCTGGAGGTGGCCGTGCAC CTGATTCTCTATGTGCGCGAGGTCTACCCGGTGGGCATCTTTCAGAAA CGGAAGAAGTACAACGTGCCGGTTCAGATGTCCTGTCACCCGGAGCTG AACCAGTACATCCAGGACACACTCCACTGCGTCAAACCTCTCCTGGAG  AAGAACGATGTGGAGAAGGTGGTGGTGGTGATTTTGGATAAGGAACAC  CGCCCAGTGGAGAAGTTTGTCTTTGAGATCACTCAGCCTCCCTTGCTG  TCCATCAATTCAGACTCCCTCCTGTCTCATGTGGAGCAGCTGCTTCGAG  CCTTCATCCTTAAGATTAGTGTGTGTGATGCTGTCCTGGATCACAACC  CTCCAGGCTGCACATTTACAGTCCTCGTGCACACAAGAGAAGCTGCTA  CTCGAAACATGGAGAAGATACAGGTCATCAAGGACTTCCCATGGATC  CTGGCAGATGAACAGGATGTCCACATGCACGACCCCCGCTTGATACCC  CTAAAAACCATGACGTCGGACATTTTAAAGATGCAGCTCTACGTTGAA  GAGCGAGCGCATAAGAACAGCTGAGGTACCCCGGG; mREV7_shRNA  resistant_L186A/Q200A/Y202A: CGCCGCGAATTCCGCCACCATGACCACC  CTCACGCGCCAAGACCTCAACTTTGGCCAAGTGGTGGCTGACGTGCTC  TCCGAGTTCCTGGAGGTGGCCGTGCACCTGATTCTCTATGTGCGCGAG  GTCTACCCGGTGGGCATCTTTCAGAAACGGAAGAAGTACAACGTGCC  GGTTCAGATGTCCTGTCACCCGGAGCTGAACCAGTACATCCAGGACAC  ACTCCACTGCGTCAAACCTCTCCTGGAGAAGAACGATGTGGAGAAGG  TGGTGGTGGTGATTTTGGATAAGGAACACCGCCCAGTGGAGAAGTTT  GTCTTTGAGATCACTCAGCCTCCCTTGCTGTCCATCAATTCAGACTCCC  TCCTGTCTCATGTGGAGCAGCTGCTTCGAGCCTTCATCCTTAAGATTAG  TGTGTGTGATGCTGTCCTGGATCACAACCCTCCAGGCTGCACATTTAC  AGTCCTCGTGCACACAAGAGAAGCTGCTACTCGAAACATGGAGAAGA  TACAGGTCATCAAGGACTTCCCATGGATCCTGGCAGATGAACAGGATG  TCCACATGCACGACCCCCGCGCTATACCCCTAAAAACCATGACGTCGG  ACATTTTAAAGATGGCTCTCGCTGTTGAAGAGCGAGCGCATAAGAAC  AGCTGAGGTACCCCGGG; mREV7_ shRNAresistant _C70R: CGCCGCGAA  TTCCGCCACCATGACCACCCTCACGCGCCAAGACCTCAACTTTGGCCA  AGTGGTGGCTGACGTGCTCTCCGAGTTCCTGGAGGTGGCCGTGCACCT  GATTCTCTATGTGCGCGAGGTCTACCCGGTGGGCATCTTTCAGAAACG  GAAGAAGTACAACGTGCCGGTTCAGATGTCCTGTCACCCGGAGCTGAA  CCAGTACATCCAGGACACACTCCACCGCGTCAAACCTCTCCTGGAGAA  GAACGATGTGGAGAAGGTGGTGGTGGTGATTTTGGATAAGGAACACC  GCCCAGTGGAGAAGTTTGTCTTTGAGATCACTCAGCCTCCCTTGCTGT  CCATCAATTCAGACTCCCTCCTGTCTCATGTGGAGCAGCTGCTTCGAG  CCTTCATCCTTAAGATTAGTGTGTGTGATGCTGTCCTGGATCACAACC  CTCCAGGCTGCACATTTACAGTCCTCGTGCACACAAGAGAAGCTGCTA  CTCGAAACATGGAGAAGATACAGGTCATCAAGGACTTCCCATGGATC  CTGGCAGATGAACAGGATGTCCACATGCACGACCCCCGCTTGATACCC  CTAAAAACCATGACGTCGGACATTTTAAAGATGCAGCTCTACGTTGAA GAGCGAGCGCATAAGAACAGCTGAGGTACCCCGGG. Using pEGFPmREV7R, C70R and L186A/Q200A/Y202A mutants as templates, Gateway compatible pMSCV-GFP or pLenti6-UBC (Invitrogen)-based REV7 truncated or REV7 mutated constructs were amplified by PCR using the following primers: forward: 59-GGGGACAACTTTGTACAAAAAAGTTGGCATGACCACCCTCACGCGC CAA-39; reverse: mREV7R (full-length for wt REV7, C70R REV7, L186A/Q200A/ Y202A REV7): 59-GGGGACAACTTTGTACAAGAAAGTTGGGTATTCAGC TGTTCTTATGCGCTCGCTC-39; mREV7R(1-140aa): 59-GGGGACAACTTT GTACAAGAAAGTTGGGTATTCAGTTGTGATCCAGGACAGC-39; mREV7R (1-183aa): 59-GGGGACAACTTTGTACAAGAAAGTTGGGTATTCAGTCGT GCATGTGGACATCCTG-39. PCR products were purified using PCR purification kit (Roche) and then subjected to BP (BP-clonase II, Invitrogen) and LR (LRclonase II, Invitrogen) reaction according to manufacturer's instructions. Wildtype 53BP1 and 53BP1 20AQ constructs were previously described 19 . All the constructs were verified by sequencing. siRNA, cDNA transfection and cDNA transduction. SMARTpool siRNAs targeting mouse Ctip (siGENOME: M-055713-02, Thermo Scientific) and non-targeting control were transfected into cells using Dharmacon 1 transfection reagent (Thermo Scientific). After 48 h, cells were subjected to western blot and a track assay. siRNAs against 53bp1, Rnf8 or Rnf168 were transfected into cells using Lipofectamine RNAiMax according to the manufacturer's instruction. The sequences of 53bp1 siRNA: 59-GAGAGCAGAUGAUCCUUUA-39 (ref. For pEGFP-based constructs, transient transfection was done using X-treme GENE HP DNA transfection reagent (Roche) according to the manufacturer's manual. GFP-positive cells were sorted by flow cytometry and subjected to western blotting and immunofluorescence staining.
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For pMSCV-GFP (retrovirus)-based constructs, transient transfection was done using X-treme GENE HP DNA transfection reagent in phoenix cells and the medium was refreshed after 24 h. Retroviruses were collected 48 h after transfection, and then target cells were infected for two consecutive periods of 12 h using fresh virus. The medium was refreshed after retrovirus infection and the cells were selected with blasticidin.
For pLenti6-UBC (lentivirus) based constructs, together with the packaging plasmids p59, p60 and p61, transient transfection was done using X-treme GENE HP DNA transfection reagent in 293T cells and the medium was refreshed after 24 h. Lentiviruses were collected 48 h after transfection and then target cells were infected for two consecutive periods of 12 h using fresh virus. The medium was refreshed after lentivirus infection and the cells were selected with blasticidin. Mice, generation of PARPi-resistant mouse mammary tumours. All mouse experiments were approved by the Animal Experiments Review Board of the Netherlands Cancer Institute (Amsterdam), complying with Dutch legislation. Olaparibresistant KB1P(M)-and AZD2461-resistant KB1P mouse mammary tumours were generated as described 7 . In this study we analysed a total of 55 PARPi-resistant and 52 PARPi-sensitive tumours derived from 13 individual KB1P(M) and 10 individual KB1P donor tumours.
To generate mouse mammary tumours from cell lines, 5 3 10 5 cells were orthotopically transplanted into 6-week-old female wild-type FVB/N_Ola129 mice as reported previously 7 . Mice were randomized to the PARPi or untreated control groups. RT-qPCR. Total RNA was isolated from cells using the high pure RNA isolation kit (Roche). cDNA was made from 1 mg RNA with the GoScript Reverse Transcription system (Promega). For the quantitative PCR cDNA, Primer Fw&Rv (400 nM) and Lightcycler 480 SYBR Green I Master (Roche) were applied in a Lightcycler 480 96-well plate (Roche). The SYBR green signals were measured with Lightcycler 480 II (Roche). The C p value of the gene of interest was subtracted from the housekeeping gene. This value was put in the power of 2 and this was also done for the s.d. The primer sequences used in this study are as follows: Mouse Hprt forward: 59-CTGGTGAAAAGGACCTCTCG-39; mouse Hprt reverse: 59-TGAAGTACTCA TTATAGTCAAGGGCA-39; mouse Rev7 forward: 59-ACACTCCACTGCGTCA AACC-39; mouse Rev7 reverse: 59-AAAGACAAACTTCTCCACTGGGC-39; mouse Rev1 forward: 59-ACAGGATTGCTTGGTGCCTGTG-39; mouse Rev1 reverse: 59-TGAAGTCCGCGTTGCTCTTCTC-39; mouse Rev3 forward: 59-AAGAGAT GTCACAGACAGGCCC-39; mouse Rev3 reverse: 59-AGTTAGACAGCCGCTG TTGTGC-39; mouse aGLT forward: 59-GACATGATCACAGGCACAGG-39; mouse aGLT reverse: 59-TTCCCCAGGTCACATTCATCGT-39; mouse mGLT forward: 59-TAGTAAGCGAGGCTCTAAAAAGCAT-39; mouse mGLT reverse: 59-AGAACAGTCCAGTGTAGGCAGTAGA-39; mouse Aid forward: 59-GAAA GTCACGCTGGAGACCG-39; mouse Aid reverse: 59-TCTCATGCCGTCCCTT GG-39. Human HPRT-P1 (primers pair 1) forward: 59-GCAGACTTTGCTTTC CTTGG-39; human HPRT-P reverse: 59-ACACTTCGTGGGGTCCTTTT-39; human HPRT-P2 forward: 59-TGCTCGAGATGTGATGAAGG-39; human HPRT-P2 reverse: 59-AATCCAGCAGGTCAGCAAAG-39; human REV7-P1 forward: 59-TGCTGTCCATCAGCTCAGAC-39; human REV7-P1 reverse: 59-TCT TCTCCATGTTGCGAGTG-39; human REV7-P2 forward: 59-GCTCACACGAC AAGACCTCA-39; human REV7-P2 reverse: 59-GACCGGCACGTTGTACTT CT-39; mouse 53bp1 forward: 59-TCAGCCAAACAGGACAAGCA-39; mouse 53bp1 reverse: 59-GCAGAATCTTCAGCAGCAAGG-39. Western blotting. Cells were washed with ice-cold PBS and lysed on ice for 30 min with RIPA lysis buffer supplemented with three protease inhibitors (P8340, P5726, P0044; Sigma-Aldrich). Protein concentration was determined by the Bradford Protein Assay Kit (Bio-Rad) and a calibration standard curve created from the BSA. The samples were prepared for loading by adding 43 sample buffer (Invitrogen) and heating the samples at 70 uC for 10 min. Total proteins were separated by SDS-PAGE on 3-8% Tris-acetate (for 53BP, RIF1) or 4-12% Bis-Tris gradient gels (all others). Next, proteins in the gel were electrophoretically transferred to PVDF membrane (Millipore) (for REV7, ACTB, a-tubulin) or to NC membranes (Invitrogen) (all others) and then the membrane was blocked in 5% milk with Tris-buffered saline Triton X-100 buffer (100 mM Tris, pH 7.4, 500 mM NaCl, 0.1% Triton X-100) (TBS-T0.1%). Membranes were incubated with primary antibodies in 5% milk in TBS-T0.1% overnight at 4 uC. Horseradish peroxidase (HRP)-conjugated secondary antibody incubation was performed for 1 h at room temperature in 5% milk in TBS-T0.1% and signals were visualized by ECL. Primary antibodies used in this study were as follows: mouse anti-REV7 (612266, BD Biosciences), 1:5,000 dilution; rabbit anti-53BP1 (NB100-304, Novus), 1:1,000 dilution; rabbit anti-53BP1 (A300-272A, Bethyl), 1:5,000 dilution; rabbit anti-CTIP (ab70163, Abcam), 1:1,000 dilution; mouse anti-a-tubulin (T6074, Sigma), 1:5,000 dilution; mouse anti-ACTB (MAB1501R, Millipore), 1:5,000 dilution; rabbit anti-mouse RIF1 (SK1316) (ref. 19 ), 1:2,000 dilution; mouse anti-RNF8 (B-2, Santa Cruz), 1:1,000 dilution; rabbit anti-RNF168 (ref. 27), 1:5,000 dilution; mouse anti-GAPDH (1D4, GeneTex) 1:1,000 dilution. Secondary antibodies used in this study were as follows: polyclonal rabbit anti-mouse immunoglobulins/HRP (P0161, Dako), 1:10,000 dilution; polyclonal swine anti-rabbit immunoglobulins/HRP (P0217, Dako), 1:10,000 dilution.
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Immunofluorescence. Cells were grown on glass coverslips (12 mm) in 24-well plates. To induce ionizing radiation-induced foci, cells were c-irradiated (10 Gy) and compared to non-irradiated controls 5 h after ionizing radiation. For this purpose the cells were pre-extracted using cold CSK buffer (10 mM HEPES-KOH, pH 7.9, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2, 1 mM EGTA and 0.5% (v/v) Triton X-100) on ice for 5 min and then cold CSS buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 1% (v/v) Tween and 0.5% (w/v) sodium deoxycholate) on ice for 5 min. Cells were washed with PBS11 (PBS with 1 mM CaCl 2 and 0.5 mM MgCl 2 ) and fixed using 2% PFA/PBS11 for 20 min at room temperature. Fixed cells were washed three times with PBS11 and stored at 4 uC. The cells were incubated 20 min in 0.2% Triton X-100/PBS11 to be permeabilized. Then the cells were washed three times in staining buffer (PBS11: 1% BSA, 0.15% glycine, 0.1% Triton X-100), incubated for 30 min in staining buffer at room temperature, incubated with the first antibody for 2 h at room temperature in staining buffer, washed three times in staining buffer, incubated with the second antibody for 1 h at room temperature in staining buffer and washed three times in staining buffer. Next, the cells were counter-stained with DAPI for 5 min, washed in staining buffer, washed in PBS11, mounted in Vectashield and sealed with nail polish. Primary antibodies used in this study were as follows: rabbit anti-RAD51 (70-001, BioAcademia), 1:20,000 dilution; rabbit anti-53BP1 (A300-272A, Bethyl), 1:4,000 dilution. Secondary antibodies used in this study were as follows: Alexa Fluor 568 F(ab') 2 Fragment goat anti-rabbit (A21069, Invitrogen), 1:1,000 dilution; Alexa Fluor 488 anti-mouse antibody (A11001, Invitrogen), 1:1,000 dilution.
For REV7 staining in MEF cells, cells cultured on coverslips were treated with 10 Gy IR and allowed to recover for 4 h. Cells were then washed with PBS, preextracted with 0.5% Triton X-100 solution for 3 min and fixed with 3% paraformaldehyde for 12 min. Coverslips were washed with PBS and then immunostained with REV7 antibody (612266, BD Biosciences, 1:200 dilution) and anti-cH2AX or anti-53BP1 in 5% goat serum for 1 h at room temperature. Coverslips were washed and incubated with secondary antibodies conjugated with rhodemine or FITC for 30 min at room temperature. Cells were then stained with DAPI to visualize nuclear DNA. The coverslips were mounted onto glass slides with anti-fade solution. For RIF1 staining in MEF cells, wild-type MEFs stably transduced with indicated shRNAexpressing lentiviruses were examined for RIF1 foci following neocarzinostatin treatment. Automated quantification of RIF1 foci following mock and neocarzinostatin treatment was performed using Cell-Profiler software (Broad Institute). Laser irradiation of human cells and immunofluorescence staining. Cells were grown on plastic disks (17 mm diameter) that were cut using CNC cutter from the bottom of standard 10-cm cultivation dish (TPP) ultraviolet-sterilized and placed inside the wells of a 12-well plate. BrDU (0.5 mM) was added into siRNA-transfected cells 40 h after the transfection to pre-sensitize cells towards UV-A wavelength. Twenty-four hours after BrdU addition, the plastic disks with cells were removed and covered by a coverslip and immediately placed inside Zeiss AxioObserver Z.1 inverted microscope combined with LSM 780 confocal module. Cells were irradiated at 20 uC via340 water immersion objective (Zeiss C-Apo 403/1.2W DICIII), using 355 nm 65 mW laser set on 100% power. The total laser dose that can be further manipulated by the amount of irradiation cycles was empirically set to six irradiation cycles. Laser track was pre-defined to cover all the cells within the acquisition area with at least one stripe across the nucleus. After the irradiation process the coverslip was gently removed and plastic disk was quickly placed back into the same well of the 12-well plate and incubated for another 45 min at standard cultivation conditions. The plastic disks with laser-irradiated cells were first processed by pre-extraction at 4 uC. It involves washing by PBS (4 uC), equilibration for 2 min in sucrose buffer 1 (10 mM PIPES, pH 6.8, 100 mM NaCl, 1.5 mM MgCl 2 and 300 mM sucrose) on ice and then pre-extraction for 15 min on ice, on slowmoving shaker using sucrose buffer 2 (10 mM PIPES, pH 6.8, 100 mM NaCl, 1.5 mM MgCl 2 , 300 mM sucrose, 0.5% Triton X-100, 5 mg ml 21 leupeptin, 2 mg ml 21 aprotinin, 0.1 mM phenylmethanesulfonylfluoride (PMSF), 1 mM dithiothreitol (DTT)). After the pre-extraction cells were washed by PBS (4 uC) and fixed by 4% paraformaldehyde (PFA) for 15 min at room temperature. PFA was washed out three times by PBS. The disks were further processed as standard coverslips (that is, blocking in blocking solution (DMEM plus 20% FCS) for 1 h followed by incubation with primary antibodies involving REV7 (BD Bioscience, mouse, 1:200), pS139-H2AX (Cell Signaling, 20E3, rabbit, 1:300) and 53BP1 (Santa Cruz, H-300, rabbit 1:400) for 2 h, and with appropriate secondary antibodies coupled to Alexa Fluor 488 and Alexa Flour 568 fluorophores (dilution 1:1,000) (Life Technologies). Both primary and secondary antibodies were dissolved in the blocking solution. After washes in PBS, the disks were incubated in 1 mg ml 21 DAPI in dH 2 O at room temperature for 5 min and air dried. Dried disks were placed on a standard microscopy glass (cell layer face up) and anchored by two rubber bands laced over the glass. Stained cells were mounted using VectaShield (Vector Labs) mounting medium and covered by a coverslip. The samples were examined using Zeiss AxioObserver Z.1 inverted microscope combined with LSM 780 confocal module using 340 oil objective (Zeiss EC PlnN 403/1.3 Oil DICII). It means that after the first acquisition the plastic disk and the microscopy glass was marked by diamond cutter (to ensure same positioning of the disk in the future), the coverslip was gently removed and disk was washed three times in PBS, 0.5% Tween to remove the mounting medium. Next, the disk was incubated in the 13 Re-Blot solution (ReBlot Plus Mild, Millipore) for 30 min on a slow moving shaker. The solution was washed out three times in PBS. Such sample was ready for new staining procedure involving new set of primary and secondary antibodies following the same protocol as described above. In situ analysis of RAD51 foci formation. Five matched PARPi-resistant and -sensitive KB1P(M) tumours were orthotopically transplanted into wild-type FVB/ N recipient mice. When tumours reached ,500 mm 3 in volume, the mice were randomized to be either irradiated (dose: 15 Gy) using a CT-guided high precision cone beam micro-irradiator (X-RAD 225Cx) or left untreated. As a positive control a BRCA1-proficient KP tumour was taken along. Two hours after irradiation the tumours were taken out and fixed in 4% formalin. Immunofluorescence staining was performed on FFPE slides. RAD51 foci were detected using a non-commercial antibody provided by R. Kanaar in a dilution of 1:5,000. 53BP1 foci were detected using rabbit anti-53BP1 (A330-272A, Bethyl), diluted 1:500. As a secondary antibody goat-anti rabbit-Alexa Fluor568 (Invitrogen) was used at a dilution of 1:1,000 (2 mg ml
21
). Images were taken by a 'blinded' investigator using a confocal microscope (Leica SP5, Leica Microsystems GmbH), equipped with a 3100 objective. For each tumour five random areas (246 3 246 mm) were imaged. Image stacks (,four slices) were analysed in ImageJ, using an in-house developed macro to automatically and objectively evaluate the RAD51 foci. In brief, nuclei were segmented by thresholding the (median-filtered) DAPI signal, followed by a watershed operation to separate touching nuclei. For every z-stack the maximum-intensity projection of the foci signal was background-subtracted using a difference of gaussians method. Next, for each nucleus, foci candidates were identified as locations where the resulting pixel values exceeded the background by a factor (typically tenfold) times the median standard deviation of all nuclei in the image. In combination with additional filters discriminating for foci size and absolute brightness this procedure yielded a robust and reliable foci count for all nuclei. Results were validated by visual inspection. REV7 recruitment to local laser-induced DNA damage sites. pEGFP-REV7 or pEGFP and 53BP1-mCherry were co-transfected into Brca1 2/2 p53 2/2 cells using X-treme GENE HP DNA Transfection Reagent according to the manufacturer's manual. GFP and mCherry double-positive cells were sorted by flow cytometry and seeded onto coverslips. Cells were sensitized by pre-incubation with Hoechst33342 and were subsequently irradiated using a 405-nm diode laser (363 objective, 0.99 mW, 60% laser power, 50 s) on a Leica SP5 confocal microscope equipped for live-cell imaging. EGFP-REV7 and 53BP1-mCherry recruitment in living cells was monitored by time-lapse imaging. Alpha track assay. Cells were seeded in dishes with a mylar surface as previously described 28 , allowing a-particle irradiation through the bottom of the dish. One or two hours after irradiation three times for 30 s with a 241 americium source, cells were washed once in ice-cold PBS. Subsequently, cells were extracted with cold CSK buffer (10 mM HEPES-KOH, pH 7.9, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 0.5% (v/v) Triton X-100) and cold CSS buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 1% (v/v) Tween20, 0.5% (w/v) sodium deoxycholate) for 5 min each before fixation in 4% PFA in PBS for 20 min at room temperature. Fixed cells were washed five times in PBS plus 0.1% Triton X-100 and washed once in blocking solution (0.5% BSA plus 0.15% glycine in PBS). Primary antibodies were diluted in blocking solution and cells were incubated overnight at 4 uC. After incubation, cells were washed five times with PBS plus 0.1% Triton X-100 and washed once in blocking solution. Secondary antibodies were diluted in blocking solution and cells were incubated at room temperature for at least 1 h. Afterwards, cells were washed five times in PBS plus 0.1% Triton X-100 and once in PBS. Finally, mylar films were glued on glass slides and cells were mounted using Vectashield with DAPI. For quantification, at least 100 53BP1 or MRE11-positive tracks were scored for the presence of RPA. Primary antibodies used in this study were as follows: rabbit anti-53BP1 (NB100-304, Novus), 1:1,000 dilution; mouse anti-RPA2 (Ab2175, Abcam), 1:500 dilution; MRE11 antibody 29 , 1:200 dilution. Secondary antibodies used in this study were as follows: Alexa Fluor 594 goat antirabbit IgG (A 31631, Invitrogen), Alexa Fluor 488 goat anti-mouse IgG (A11001, Invitrogen). BrdU propidium iodide cell cycle assay. Cells were seeded in 6-cm dishes and attached overnight. The next day, cells were incubated for 15 min with 5 mM BrdU in growth medium, trypsinized, washed in PBS and fixed in 70% ethanol overnight. Fixed cells were washed in PBS, resuspended in pepsin solution (5 mg pepsin in 10 ml 0.1 N HCl) and incubated for 20 min at room temperature. Subsequently blocking solution (0.5% Tween, 0.1% BSA in PBS) was added to wash. Next, cells were resuspended in 2 N HCl and incubated 12 min at 37 uC . To neutralize, 100 mM LETTER RESEARCH borate buffer (pH 8.5) was added and cells were pelleted. Anti-BrdU-FITC antibody (347583, BD Bioscience) was diluted in blocking solution, added to cells and incubated for 2 h on ice. Stained cells were washed once with blocking solution and resuspended in 500 ml PBS plus 12.5 ml RNaseA and 1 ml propidium iodide (P3566, Invitrogen). Cell cycle analysis was performed the next day. Survival assay of mES cells. R26 CreERT2/wt ; Brca1
SCo/D mES cells 15 were infected with hairpins targeting Rev7 or the vector control and selected with puromycin. Expression of mouse Brca1 was switched off by overnight incubation with 0.5 mM 4-hydroxytamoxifen. Four days after switching, 5,000 cells of the indicated groups were seeded per well into 6-well plates and assayed for growth. Surviving colonies were fixed in formalin and stained with crystal violet. DR-GFP for HR assay. R26 CreERT2/wt ; Brca1
SCo/D mES cells were targeted with a modified version of the p59X DR-GFP construct as described 30 . To allow experiments on a p53-deficient background, cells were infected with a lentiviral p53 shRNA (59-AGAGTATTTCACCCTCAAGAT-39) using a pLKO1 vector provided with a neomycin resistance marker. A G418-selected p53-deficient clone was subsequently infected with hairpins targeting Rev7 or the vector control and selected with puromycin. Expression of mouse Brca1 was switched off by overnight incubation with 0.5 mM 4-hydroxytamoxifen to measure the effect of Rev7 loss on HR. HR reporter assays were performed by Lipofectamine 2000 (Invitrogen) transfection of the I-SceI-mCherry plasmid, which was generated by providing the cBasI-SceI expression plasmid with CMV-mCherry (Clontech). Forty-eight hours after transfection, mCherry/GFP double-positive cells were monitored by flow cytometry as described 15 . 53BP1 pull-down. 53BP1 pull-downs were performed as described 19 . Flag pulldowns were performed from 2 mg lysate prepared from MEFs following mock or neocarzinostatin treatment (2 h at 250 ng ml
). Control, 53BP1 and 53BP1
20AQ
immuneprecipitates were then treated with sequential low-salt (150 mM) and highsalt (500 mM) RIPA buffer washes, before re-equilibration in nuclear extract buffer (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5 mM PMSF, 0.5 mM DTT and protease inhibitors (Roche, Complete)). After incubation in Hela Nuclear Extract (2 mg), control, 53BP1 and 53BP1 20AQ complexes were washed four times in nuclear extract buffer, then eluted with triple-Flag peptide (Sigma). Immunoglobulin CSR. CH12 cells were either mock-treated or stimulated with agonist anti-CD40 antibody (0.5 mg ml Immunohistochemistry on paraffin sections. The panel of formalin-fixed, paraffinembedded archival specimens from a series of 50 human primary breast carcinomas was examined, surgically resected before any chemotherapy or radiotherapy. In parallel, sections from ten specimens of formalin-fixed, paraffin-embedded histologically normal human breast tissues were used as normal tissue controls, for immunohistochemical analysis of REV7 expression patterns. The breast carcinomas were all of the triple-negative type, defined in this cohort as having fewer than 1% tumour cells positive in standard immunohistochemical staining for oestrogen and progesterone receptor proteins, and lacking amplification of the HER2 (also known as ERBB2) gene. For the immunohistochemical analysis, 4-mm-thick sections were cut from representative blocks of the tumour tissues, the sections were deparaffinized and processed for sensitive immunoperoxidase staining with the primary mouse monoclonal antibody to REV7 (BD Biosciences, 612266, diluted 1:100). The staining procedure was essentially as described 15 , with antigen unmasking in citrate buffer, pH 6.0, for 15-20 min in a microwave oven, and overnight incubation with the primary antibody, followed by the Vectastain Elite kit (Vector Laboratories) and nickel sulfate enhancement without nuclear counterstaining 31 .
Mouse normal serum and antibody to cH2AX served as negative and positive controls, respectively. Evaluation of the staining patterns was performed by two independent observers (with very similar outcomes), including a senior oncopathologist with more than 20 years of experience with breast cancer pathology. The results were scored in the following categories, based on comparison of cancer cells with the series of normal breast tissue controls, and also the normal of cells present within each of the tumour sections. As normal breast epithelium showed reproducible positivity for REV7 protein in over 90% of cells, we considered as aberrantly decreased expression in a tumour when fewer than 70% of cancer cells were positive. In addition to the percentage of stained tumour cells, staining intensity was classified as either normal (comparable with the intensity of normal cells present on each section) or aberrantly low (clearly below the intensity seen in adjacent normal cells, and up to undetectable in some cases). Overall, while 6 out of 47 informative cases showed concomitantly aberrant fraction of REV7-stained cells and reduced intensity of staining, 12 additional cases showed less pronounced defects limited to either staining intensity or reduced percentage of cancer cells, respectively. As the primary goal of these analyses was to establish a detection assay for REV7 on archival tissue specimens and to assess the frequency of potentially REV7-deficient breast tumours, correlation analyses with clinical parameters including treatment outcome remain to be performed on larger cohorts of patients in the future. Statistics. Statistical tests used were log-rank test, t-test and Mann-Whitney U test, with P , 0.05 as the significance level. No statistical methods were used to predetermine sample size. cells with or without Rev7 loss exposed to olaparib. i, REV7 protein levels were determined by western blotting of lysates derived from KB1P-G3 cells transduced with the indicated constructs. j, Overall survival of mice with KB1P-B11-derived Rev7-depleted or control tumours treated with one regimen of 50 mg kg 21 olaparib daily for 28 days or left untreated. The P value was calculated using the log-rank test. k, l, Relative tumour growth of individual KB1P-G3-(k) and KB1P-B11-(l) derived Rev7-depleted or control tumours treated with one regimen of 50 mg kg 21 olaparib daily for 28 days or left untreated. c, Quantification of the clonogenic assays using absorbance of crystal violet at 590 nm. The data represent mean 6 s.d. All the groups were normalized by the absorbance of the vector control and showed significant differences to the control (P , 0.01, t-test). human cells. a-c, Human REV7 recruitment to sites of laser-induced DNA damage was analysed in U2OS cells transfected with siRNAs targeting RNF8 (siRNF8), RNF168 (siRNF168) (a), 53BP1 (si53BP1) (c) and GFP (siGFP). RNF8 and RNF168 protein levels were determined by western blotting (b) using lysates derived from U2OS cells transfecting with the indicated siRNAs. d, For the quantification of the REV7 signal within laser-induced DNA damage stripes, a minimum of 100 striped (that is, cH2AX-positive) cells were analysed for the presence of the REV7 signal in two independent experiments. Scale bars, 50 mm. e, RAD51 focus (red) formation in KB1P-B11 cells before and 5 h after 10 Gy ionizing radiation. Scale bar, 10 mm. f, Quantification of RAD51 foci in KB1P-B11 cells in the presence or absence of REV7 depletion. At least 150 cells were analysed per group in three independent experiments each. Error bars indicate s.d.; IR denotes 5 h after 10 Gy ionizing radiation. g, Western blotting analysis of REV7-depleted KB1P-G3 cells transfected with human REV7-GFP or Rev7-shRNA-resistant mouse REV7-GFP fusion proteins. h, Same as in e and f using the ATM inhibitor KU55933 with or without IR (5 h after 10 Gy ionizing radiation). i, Long-term clonogenic survival assay of KB1P-G3 cells exposed to olaparib in the presence or absence of KU55933 pre-treatment. LETTER RESEARCH
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